CA2959280C - Vaccine - Google Patents

Vaccine Download PDF

Info

Publication number
CA2959280C
CA2959280C CA2959280A CA2959280A CA2959280C CA 2959280 C CA2959280 C CA 2959280C CA 2959280 A CA2959280 A CA 2959280A CA 2959280 A CA2959280 A CA 2959280A CA 2959280 C CA2959280 C CA 2959280C
Authority
CA
Canada
Prior art keywords
denv
ediii
vaccine
hbsag
dengue virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2959280A
Other languages
English (en)
French (fr)
Other versions
CA2959280A1 (en
Inventor
Navin Khanna
Viswanathan RAMASAMY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Centre for Genetic Engineering and Biotechnology
Original Assignee
International Centre for Genetic Engineering and Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Centre for Genetic Engineering and Biotechnology filed Critical International Centre for Genetic Engineering and Biotechnology
Publication of CA2959280A1 publication Critical patent/CA2959280A1/en
Application granted granted Critical
Publication of CA2959280C publication Critical patent/CA2959280C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Cartons (AREA)
  • Packaging Of Annular Or Rod-Shaped Articles, Wearing Apparel, Cassettes, Or The Like (AREA)
CA2959280A 2014-09-01 2015-08-21 Vaccine Active CA2959280C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2478/DEL/2014 2014-09-01
IN2478DE2014 2014-09-01
PCT/IB2015/056352 WO2016034974A1 (en) 2014-09-01 2015-08-21 Vaccine

Publications (2)

Publication Number Publication Date
CA2959280A1 CA2959280A1 (en) 2016-03-10
CA2959280C true CA2959280C (en) 2023-09-26

Family

ID=55439184

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2959280A Active CA2959280C (en) 2014-09-01 2015-08-21 Vaccine

Country Status (18)

Country Link
US (3) US10189877B2 (enExample)
EP (2) EP3188755B1 (enExample)
JP (3) JP6983653B2 (enExample)
CN (1) CN107074968B (enExample)
CA (1) CA2959280C (enExample)
CY (1) CY1123664T1 (enExample)
ES (1) ES2821480T3 (enExample)
HR (1) HRP20201523T1 (enExample)
HU (1) HUE053284T2 (enExample)
LT (1) LT3188755T (enExample)
MX (2) MX385222B (enExample)
MY (1) MY201688A (enExample)
PL (1) PL3188755T3 (enExample)
PT (1) PT3188755T (enExample)
RS (1) RS61000B1 (enExample)
SI (1) SI3188755T1 (enExample)
SM (1) SMT202000589T1 (enExample)
WO (1) WO2016034974A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2821480T3 (es) * 2014-09-01 2021-04-26 Int Centre For Genetic Engineering And Biotechnology Vacuna
EP3621645A4 (en) * 2017-05-10 2021-01-27 University of Massachusetts BIVALENT VACCINES AGAINST DENGUE / HEPATITIS B

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
JP3954643B2 (ja) * 1991-11-16 2007-08-08 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム マラリア原虫由来のＣＳおよびＨＢｓＡＧ間のハイブリッド蛋白質
FR2741077B1 (fr) * 1995-11-14 1998-01-23 Pasteur Institut Vaccin polyvalent anti-dengue
WO2007034507A2 (en) * 2005-09-20 2007-03-29 International Centre For Genetic Engineering And Biotechnology Tetravalent dengue specific domain iii based chimeric recombinant protein
WO2008152652A2 (en) * 2007-06-12 2008-12-18 International Centre For Genetic Engineering And Biotechnology A dengue envelope domain iii-based tetravalent protein vaccine
WO2010043977A2 (en) * 2008-10-13 2010-04-22 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
CN101962411B (zh) * 2009-07-24 2012-09-05 中国疾病预防控制中心病毒病预防控制所 登革病毒血清学早期诊断试剂
CN102906266A (zh) * 2010-05-21 2013-01-30 高等教育联邦系统-匹兹堡大学 登革病毒通用序列及其使用方法
CN103193870B (zh) * 2013-04-22 2014-10-22 中国人民解放军第三军医大学 一种登革病毒简并疫苗及其应用
ES2821480T3 (es) * 2014-09-01 2021-04-26 Int Centre For Genetic Engineering And Biotechnology Vacuna

Also Published As

Publication number Publication date
SI3188755T1 (sl) 2021-03-31
EP3685852A1 (en) 2020-07-29
CY1123664T1 (el) 2022-03-24
HRP20201523T1 (hr) 2021-03-05
WO2016034974A1 (en) 2016-03-10
JP2020162611A (ja) 2020-10-08
RS61000B1 (sr) 2020-11-30
US10815280B2 (en) 2020-10-27
US11945842B2 (en) 2024-04-02
CA2959280A1 (en) 2016-03-10
JP7333373B2 (ja) 2023-08-24
US20210122787A1 (en) 2021-04-29
ES2821480T3 (es) 2021-04-26
MX385222B (es) 2025-03-14
JP6985458B2 (ja) 2021-12-22
US20190194261A1 (en) 2019-06-27
BR112017004008A2 (pt) 2018-01-23
CN107074968B (zh) 2021-03-12
PL3188755T3 (pl) 2021-01-25
HUE053284T2 (hu) 2021-06-28
JP2022031791A (ja) 2022-02-22
LT3188755T (lt) 2020-12-28
JP2017526366A (ja) 2017-09-14
SMT202000589T1 (it) 2020-11-10
CN107074968A (zh) 2017-08-18
JP6983653B2 (ja) 2021-12-17
US10189877B2 (en) 2019-01-29
EP3188755B1 (en) 2020-08-05
MY201688A (en) 2024-03-13
MX2017002621A (es) 2017-07-28
MX2021006543A (es) 2021-10-13
US20170240601A1 (en) 2017-08-24
EP3188755A1 (en) 2017-07-12
PT3188755T (pt) 2020-09-29

Similar Documents

Publication Publication Date Title
US20210355167A1 (en) Neutralising antibody against dengue for use in a method of prevention and/or treatment of zika infection
Poggianella et al. Dengue E protein domain III-based DNA immunisation induces strong antibody responses to all four viral serotypes
AU2015279375B2 (en) A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
De Lorenzo et al. Zika virus-like particles bearing a covalent dimer of envelope protein protect mice from lethal challenge
US11945842B2 (en) Tetravalent dengue vaccine
WO2015019253A2 (en) Anti-dengue virus genetic vaccine based on the envelope protein ectodomains
HK40032428A (en) Vaccine
US20220372079A1 (en) Resurfaced dengue virus and ziki virus glycoprotein e diii variants and uses thereof
JP2011502521A (ja) Ｈｉｖ−１外被糖タンパク質オリゴマー及び使用方法
US10772949B2 (en) Dengue virus glycoprotein E DIII variants and uses thereof
JP7221995B2 (ja) フラビウイルスの成熟ウイルス様粒子
Chen et al. Selection of immunodominant fragments from envelope gene for vaccine against Japanese encephalitis virus in DNA priming–protein boosting protocols
WO2010106509A2 (en) Hcv-derived polypeptides and uses thereof
WO2025146159A1 (zh) 针对寨卡/登革病毒的重组抗原、其疫苗组合物及其应用
WO2017031280A1 (en) Fusion proteins that include dengue antigens and methods of use
BR112017001340B1 (pt) Epítopo de dímero e, composição, composição farmacêutica, kit, método para a síntese do ede e para produzir um anticorpo ou porção de ligação ao antígeno do mesmo, método in vitro para monitorar a progressão ou regressão de uma infecção por vírus da dengue ou prever a evolução no tempo da mesma, para diagnosticar uma infecção por vírus da dengue e para monitorar o sucesso de um protocolo de vacinação contra uma infecção de vírus da dengue e usos dos mesmos

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200818

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240816

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240816